Schering supreme Hubertus Erlen commented, “It is not possible for Schering to maintain its independence, given the Bayer offer.” The new entity would have combined net sales worth approximately $18.4 billion and would create a health care unit ranked amongst the world’s top 12 companies. It would also add Schering’s Yasmin – one of the world’s highest selling oral birth control drugs with sales of $718.45 million in 2005 – to Bayer’s portfolio.
For Complete IIPM-Article, Click IIPM-Business and Economy
Source IIPM-Editorial,2006
For Complete IIPM-Article, Click IIPM-Business and Economy
Source IIPM-Editorial,2006
